More Evidence Of Anemia Drug Risk: FDA

Law360, New York (January 4, 2008, 12:00 AM EST) -- Two new studies being examined by the U.S. Food and Drug Administration again indicate the risks of three anemia drugs, particularly when used by patients battling certain types of cancers with chemotherapy.

According to the federal agency, the two studies show that patients with breast cancer or advanced cervical cancer who take erythropoiesis-stimulating agents, or ESAs, to fight anemia caused by their chemotherapy died sooner or had more rapid tumor growth than similar patients who were not taking the anemia medication.

The studies come on the...
To view the full article, register now.